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ABSTRACT 39 
Head and Neck Squamous Cell Carcinoma (HNSCC) remains among the most 40 
aggressive human cancers. Tumor progression and aggressiveness in SCC are largely 41 
driven by Tumor Propagating Cells (TPCs). Aerobic glycolysis, also known as the 42 
Warburg Effect, represents a characteristic of many cancers, yet whether this 43 
adaptation is functionally important in SCC, and at which stage, remains poorly 44 
understood. Here, we show that the NAD+-dependent histone deacetylase Sirtuin 6 45 
(SIRT6) is a robust tumor suppressor in SCC, acting as a modulator of glycolysis in 46 
these tumors. Remarkably, rather than a late adaptation, we find enhanced glycolysis 47 
specifically in TPCs. More importantly, using single cell RNA sequencing of TPCs, we 48 
identify a subset of TPCs with higher glycolysis and enhanced pentose phosphate 49 
pathway and glutathione metabolism, characteristics that are strongly associated with a 50 
better antioxidant response. Altogether, our studies uncover enhanced glycolysis as a 51 
main driver in SCC, and, more importantly, identify a subset of TPCs as the cell-of-52 











Tumor propagating cells (TPCs or cancer stem cells) in squamous cell carcinoma 64 
(SCC) are responsible for sustaining primary tumors and are able to re-populate the 65 
entire tumor after transplantation due to their self-renewal and differentiation 66 
capacity1. As such, TPCs have emerged as attractive therapeutic targets2. Although 67 
genetic drivers, such as the surface marker CD34 and the transcription factor SOX23-6 68 
have been identified in TPCs, the specific metabolic characteristics of these cells 69 
remain poorly investigated.  70 
Metabolic reprogramming has emerged as a critical hallmark of cancer7,8. In 71 
particular, increased glycolysis and lactate production under normoxia (aerobic 72 
glycolysis) represent one of the best-described characteristics of many tumors. Such 73 
an adaptation, also known as the Warburg effect, provides transformed cells with 74 
intermediate metabolites for biomass, while balancing cellular redox status for 75 
continuous proliferation9,10. SIRT6, a member of the NAD+-dependent protein 76 
deacylases known as sirtuins, negatively regulates HIF-1α-dependent glycolysis gene 77 
expression (e.g. the glucose transporter GLUT1, pyruvate dehydrogenase kinase 1 78 
(PDK1), and lactate dehydrogenase-A (LDHA) as an H3K9/H3K56 deacetylase, 79 
affecting glucose homeostasis11,12. Sirt6-deficient cells exhibit aggressive tumor 80 
formation through enhanced aerobic glycolysis in colon cancer13, and increased 81 
expression of oncofetal proteins in pancreatic cancer14, emphasizing a pivotal role for 82 
SIRT6 in glucose metabolism and tumorigenesis. 83 
In this study, we find that enhanced glycolysis in a model of SIRT6 loss enriches 84 
for CD34+ TPCs, in turn resulting in a much more aggressive tumorigenic phenotype. 85 
Mechanistically, highly glycolytic CD34+ TPCs present a distinct gene signature 86 
associated with glutathione (GSH) metabolism and stemness, thereby providing a 87 
defense against oxidative stress, which is robustly enhanced upon Sirt6 loss. Using 88 
metabolite profiling analysis, we further demonstrate that generation of antioxidants 89 
and nucleotides through the oxidative phase of the pentose phosphate pathway 90 
(oxPPP) is largely responsible for the aggressive tumorigenic phenotype. Remarkably, 91 
direct metabolite measurement from in vivo tumor samples in cellular spatial 92 
resolution by MALDI-Mass Spectrometry Imaging (MSI) indicates higher glycolysis 93 
and more reduced GSH in CD34+ TPCs compared to CD34- tumor cells. Further, 94 
single cell RNA-sequencing (scRNA-seq) analysis defines a subset of TPCs with such 95 
characteristics that are functionally crucial for TPC enrichment and tumorigenic 96 
potential.  Our studies provide the first in-depth characterization of the metabolic 97 
adaptations in SCC, identifying a previously unrecognized metabolic heterogeneity 98 
within TPCs, a key feature to support antioxidant protection and nucleotide synthesis 99 
in these unique tumor-driving cells. 100 
 101 
RESULTS 102 
SIRT6 acts as a tumor suppressor in SCC by modulating aerobic glycolysis 103 
We sought to define an in vivo model of squamous cell carcinoma (SCC) to 104 
closely examine the effect of increased glycolysis in tumorigenesis and its specific 105 
subpopulations including TPCs. We reasoned whether SIRT6 could act as a tumor 106 
suppressor in squamous cell carcinoma, one of the major types of epithelial cancers, 107 
via modulation of glycolysis. Notably, SIRT6 copy number loss is associated with 108 
shorter overall survival when analyzed in patient samples of HNSCC in The Cancer 109 
Genome Atlas (TCGA, Extended Data Fig. 1a). Further, both SIRT6 copy number and 110 
expression were significantly decreased in HNSCC compared to matched normal 111 
tissue in either the Oncomine or the TCGA (Extended Data Fig. 1b-c). SIRT6 112 
expression was already observed in early-stage tumors, implicating that SIRT6 loss 113 
may be functionally important in both initiation and maintenance of SCCs (Extended 114 
Data Fig. 1b). We next analyzed SIRT6 protein expression in human HNSCC patient 115 
samples and normal skin tissues by immunohistochemistry and found that less 116 
differentiated tumors tend to have less SIRT6 expression (Extended Data Fig. 1d). 117 
Lastly, among available human cancer cell lines listed in the Cancer Cell Line 118 
Encyclopedia (CCLE), almost all HNSCC cell lines (denoted as Upper aerodigestive 119 
tract) exhibited SIRT6 loss (Extended Data Fig. 1e). Altogether, these analyses suggest 120 
a potential tumor suppressive role for SIRT6 in SCC.  121 
In order to better define the roles of Sirt6 in squamous cell carcinogenesis, we 122 
generated an in vivo Sirt6 conditional knockout (cKO) mouse model (Sirt6 F/F; K14-123 
cre+) that specifically deletes Sirt6 in the skin epithelium. These mice along with wild 124 
type (WT) animals (Sirt6 +/+; K14-cre+) were treated with DMBA (7,12-125 
dimethylbenz[a]anthracene), a known carcinogen, followed by repetitive TPA (12-O-126 
tetradecanoylphorbol-13-acetate) treatment for 14 weeks, a well-established protocol 127 
to recapitulate SCC in vivo (Fig. 1a). Remarkably, Sirt6-deficient animals showed an 128 
earlier onset of tumors (Fig. 1b) and significantly larger tumors at 14 weeks after 129 
DMBA treatment (Fig. 1c). C57BL/6 strain is known to be highly resistant to 130 
tumorigenesis in vivo, and without continuous TPA treatment existing skin tumors 131 
tend to regress15. Consistently, most of the WT tumors became smaller and regressed 132 
after discontinuing TPA treatment for more than 7 weeks. In contrast, multiple Sirt6-133 
deleted tumors remained and even grew larger (Fig. 1d). Notably, fully transformed 134 
SCC were exclusively form in Sirt6-deleted animals (Extended Data Fig. 2a). We next 135 
assessed tumor cell proliferation and detected a major increase in PCNA+ cells in 136 
Sirt6-deficient tumors (Fig. 1e). Overall, these data suggest that loss of Sirt6 137 
promotes tumor cell proliferation, resulting in enhanced tumor progression and 138 
maintenance. 139 
To directly determine whether increased glycolysis plays a functional role in 140 
driving tumor progression, we next administered an inhibitor of glycolysis, 141 
dichloroacetate (DCA), in drinking water during the DMBA/TPA treatment in vivo (Fig. 142 
1f). Inhibition of glycolysis significantly reduced tumor size in Sirt6-deficient animals 143 
(Fig. 1g), while continuous inhibition of glycolysis following TPA withdrawal 144 
completely impaired the progression of the existing tumors in Sirt6-deleted animals 145 
(Fig. 1h). These findings emphasize a critical role for aerobic glycolysis in SCC growth 146 
and maintenance. Molecularly, dysplastic proliferating cells started to express high 147 
levels of GLUT1, while normal proliferating (PCNA+) keratinocytes and hair follicular 148 
stem cells (HFSCs) barely expressed GLUT1, suggesting that increased glycolytic 149 
metabolism as an important adaptation of transformed cells, not normal proliferating 150 
cells (Extended Data Fig. 2b). In line with these results, RNA expression of Glut1 and 151 
another glycolytic gene, Ldha, was also increased in tumors compared to adjacent 152 
normal skin (Extended Data Fig. 2c). Further, GLUT1 appeared specifically expressed 153 
in tumors, particularly in tumor basal layers, compared to normal adjacent skin (Fig. 154 
1i, and Extended Data Fig. 2d, left panels). This was also true for the PDK-dependent 155 
phosphorylated form of PDH (pyruvate dehydrogenase complex) (Fig. 1i, and 156 
Extended Data Fig. 2d, middle panels), the rate-limiting enzyme that converts 157 
pyruvate into acetyl-CoA for usage in the TCA cycle. Phosphorylation of PDH 158 
inactivates the enzyme, forcing production of lactate instead. Mitochondria pyruvate 159 
carrier 1 (MPC1) expression was higher in more differentiated tumor cells compared 160 
to basal tumor cells (Extended Data Fig. 2d, right panels), suggesting less pyruvate 161 
entry to mitochondria in these cells. These results together indicate that tumor basal 162 
cells are exquisitely glycolytic. 163 
We next analyzed expression of SIRT6 and glycolytic genes in samples from 164 
patients’ squamous cell carcinomas. Several glycolytic genes were inversely correlated 165 
with the level of SIRT6, a phenotype observed even at early stages of carcinogenesis 166 
(Extended Data Fig. 2e). Lastly, SIRT6 low, less differentiated tumors tend to express 167 
ubiquitously higher levels of GLUT1 (Extended Data Fig. 2f). This further strengthens 168 
our mouse data and validates this in vivo model as highly relevant to human HNSCC.  169 
 170 
Increased glycolysis by Sirt6 loss enriches the number of TPCs  171 
Next, we sought to follow these GLUT1+ tumor cells and to assess their functional 172 
role in tumorigenesis. First, we analyzed the differentiation state of the GLUT1+ cells 173 
in the tumors by using keratin5 and keratin10, markers of basal progenitors and 174 
differentiated cells in skin, respectively. Most of the GLUT1+ cells co-stained with 175 
keratin5 and were mutually exclusive with keratin10 (Extended Data Fig. 3a), 176 
suggesting that less differentiated cells are particularly glycolytic. We next stained for 177 
the surface marker CD34, an established marker of TPCs. As expected, most of CD34+ 178 
cells co-expressed keratin 5 and were negative for keratin 10 (Extended Data Fig. 3b). 179 
Remarkably, most of the GLUT1+ cells were CD34+ and SOX9+, supporting the idea 180 
that glycolytic basal cells are putative TPCs (Fig. 2a, left panels). Importantly, 181 
CD34+/SOX9+ hair follicle stem cells (HFSCs) were GLUT1-, indicating that specifically 182 
the CD34+ tumor cells, rather than normal skin stem cells, benefit from enhanced 183 
glucose uptake (Fig. 2a, right panels). This is further strengthened by co-staining with 184 
GLUT1, CD34, and keratin10 in whole tumor samples and subsequent calculation of 185 
correlation values (Extended Data Fig. 3c). Similarly, α6 integrinhigh/CD34+ have much 186 
higher expression levels of GLUT1 compared to α6 integrinhigh/CD34- (Extended Data 187 
Fig. 3d). 188 
Although markers used to identify TPCs in human HNSCC remain controversial, 189 
TPCs in murine cutaneous SCC have been well defined in the past decade3-6,16-19. We 190 
attempted to analyze and prospectively isolate TPCs (α6 integrinhigh/CD34+) from 191 
Sirt6 WT or Sirt6-deleted skin tumors (Extended Data Fig. 4a). Strikingly, when we 192 
analyzed the percentage of TPCs in live lineage-selected (PI-/YFP+) tumor cells (see 193 
Methods), we found that Sirt6-deleted tumors exhibited a significant increase in TPCs 194 
(Fig. 2b, and Extended Data Fig. 4b), especially in tumors that were large (more than 195 
2.5 mm in size), compared to size-matched tumors from WT mice. We next inhibited 196 
glycolysis in vivo by treating the animals with DCA, which caused significantly 197 
decreased blood lactate and reduced phospho-PDH (S293) levels (Extended Data Fig. 198 
4c-d), both results confirming successful inhibition of glycolysis. More importantly, 199 
DCA treatment severely reduced the percentage of TPCs both in WT and Sirt6-200 
deficient tumors (Fig. 2c, and Extended Data Fig. 4b), suggesting that enhanced 201 
glycolysis could provide a unique advantage to TPCs, a phenotype exacerbated in the 202 
absence of SIRT6. All together, these results indicate that the increased tumor growth 203 
and maintenance phenotype observed in Sirt6-deleted tumors could be due to an 204 
increase in TPCs, a population uniquely glycolytic.  205 
 206 
TPCs exhibited higher glutathione metabolism and better antioxidant response 207 
In order to pinpoint mechanistic pathways that could explain the benefit of 208 
enhanced glycolysis in TPCs, we performed RNA-sequencing (Extended Data Fig. 4e-209 
f). First, we established a “common TPC gene signature”. In this analysis, we identified 210 
397 commonly upregulated genes and 191 commonly downregulated genes (Fig. 2d, 211 
and Supplementary Table 1). DAVID pathway analysis in these upregulated genes 212 
from DEGs (differentially expressed genes) of Sirt6 cKO TPC vs Sirt6 cKO α6high/CD34- 213 
(Supplementary Table 2) and DEGs of WT TPC vs WT α6high/CD34- (Supplementary 214 
Table 3) revealed upregulation of several pathways in TPCs, including glutathione 215 
metabolism, lipid metabolism, amino acid transport, and multicellular organism 216 
development (Fig. 2e, and Extended Data Fig. 4g). Some of the commonly 217 
upregulated genes were already known to be important in TPCs (e.g. Sox2, Ptk2, 218 
Ereg, etc), providing support to the quality of our data5,6,16,17.  219 
Enhanced glutathione metabolism is important for antioxidant defense, and lipid 220 
metabolism and amino acid transport are vital for cellular energy and biomass, 221 
suggesting that rewiring metabolism is pivotal in TPCs. Consistently, Sirt6-deficient 222 
TPCs exhibited higher expression of genes in glycolysis and the pentose phosphate 223 
pathway (PPP), consistent with their aggressive phenotype (Supplementary Table 4; 224 
Fig. 2f, left). Moreover, genes involved in both glutathione metabolism and redox 225 
balance, which were enriched in TPCs, were even higher in Sirt6 cKO TPCs (Fig. 2f, 226 
right). Strikingly, genes involved in stemness and carcinogenesis were expressed at a 227 
much higher level in Sirt6-deleted TPCs compared to WT TPCs, providing further 228 
rationale for the increased aggressiveness in the Sirt6-deleted tumors (Extended Data 229 
Fig. 4h). 230 
 231 
Increased oxPPP, generation of reduced glutathione (GSH) and nucleotides in 232 
SCC 233 
To gain further insights into the metabolic adaptations that can be regulated by 234 
SIRT6, we took advantage of two human SCC cell lines. In HSC2 cells that barely 235 
express SIRT6, we find that ectopic expression of SIRT6 causes repression of 236 
glycolytic gene expression, reduced H3K9/K56 acetylation (Extended Data Fig. 5a), 237 
and decreased glycolytic reserve capacity (Extended Data Fig. 5b).  Using stable 238 
isotope tracing with U-13C-glucose, we found diminished glycolytic flux towards 239 
glycolytic intermediates including fructose-6-phosphate (F6P), pyruvate and lactate 240 
(Fig. 3a, upper panel, and Extended Data Fig. 5c), and delayed 13C incorporation into 241 
ribose-5-phospohate (R5P) (Fig. 3a, middle panel), at a time when most of the cells 242 
(both in WT and H133Y) are alive (Extended Data Fig. 5d). Of note, although citrate 243 
labeling didn’t reach steady state, the flux into citrate from glycolysis via acetyl-CoA 244 
(M+2) showed similar labeling kinetics (Extended Data Fig. 5e, left panel). In addition, 245 
the flux into α-KG from glycolysis (M+2) that reached a pseudo steady state was not 246 
affected, indicating that cells sustain normal mitochondrial respiration (Extended Data 247 
Fig. 5e, right panel). Decrease in glycolysis from SIRT6 overexpression was dependent 248 
on SIRT6 enzymatic activity, since expression of the SIRT6 H133Y catalytically inactive 249 
mutant (HY) did not influence glycolysis (Fig. 3a-b, and Extended Data Fig. 5a-c). 250 
Although these experiments suggest that the enzymatic activity of SIRT6 is necessary, 251 
we cannot rule out additional, non-enzymatic roles for SIRT6 in this phenotype.  252 
The PPP consists of an oxidative phase (critical to regenerate GSH) and a non-253 
oxidative phase, which can be distinguished with 1,2-13C-glucose (depicted in Fig. 3b, 254 
upper right panel). Interestingly, the relative fraction of M+1 R5P was appreciably 255 
decreased when SIRT6 was overexpressed, while the relative fraction of M+2 R5P 256 
remained similar, indicating that the oxidative arm of the PPP was majorly affected 257 
(Fig. 3b, middle panel). In addition, sedoheptulose-7-phosphate (S7P), one of the 258 
intermediates in the non-oxidative PPP, did not show a notable difference in 13C 259 
incorporation (Fig. 3a-b, bottom panels), further confirming our findings. Lastly, 13C 260 
incorporation into DNA (M+5 isotopologue) was significantly reduced in these cells 261 
(S6WT), indicating that enhanced PPP in SIRT6 deficient tumors serves as a critical 262 
precursor in de novo nucleotide synthesis (Fig. 3c) (Pool size data is available in 263 
Supplementary Table 5).   264 
As a complementary approach, we used SCC13, a skin SCC cell line that 265 
endogenously expresses high levels of SIRT6. We observed that inducible knockdown 266 
of SIRT6 caused increased glycolytic gene expression, increased bulked H3K56Ac, and 267 
increased H3K9 acetylation specifically in glycolytic genes (Extended Data Fig. 6a-b). 268 
Consistently, a global increase in H3K56Ac is also observed in in vivo tumor samples 269 
from Sirt6 cKO animals compare to WT animals (Extended Data Fig. 6c). Intriguingly, 270 
CD34+ TPCs in WT tumor samples showed higher H3K56Ac levels compared to CD34- 271 
tumor cells, indicating that SIRT6 activity might be reduced in CD34+ TPCs, likely 272 
contributing to the enhanced glycolytic phenotype in TPCs (Extended Data Fig. 6d). 273 
Knockdown of SIRT6 also boosted glucose uptake (consumption), lactate secretion, 274 
and glycolytic capacity (Extended Data Fig. 6e-i), while enriching for the relative 275 
abundance of several glycolytic intermediates including pyruvate and lactate 276 
(Extended Data Fig. 6l). These results are indicative of a quantitative increase in 277 
glucose metabolism and glycolysis, rather than an imbalance between glycolysis and 278 
mitochondrial respiration, since the ratios of lactate secretion/glucose consumption 279 
and NAD+/NADH did not show differences (Extended Data Fig. 6h and 6j). Notably, 280 
highly glycolytic cells (shSIRT6) exhibited more GSH and less GSSG/GSH (oxidized vs 281 
reduced forms of glutathione) and lower ROS (Fig. 3d, Extended Data Fig. 6k). We 282 
also observe increased levels of several nucleotides and their precursors, consistent 283 
with what we observed in HSC2 cells (Extended Data Fig. 6m) (Pool size data is 284 
available in Supplementary Table 5).  Inhibition of SIRT6 as a driver of metabolic 285 
rewiring seems critical for tumor survival and growth, since prolonged overexpression 286 
of SIRT6 caused apoptosis of these HSC2 tumor cells, (Extended Data Fig. 7a), while 287 
knockdown of SIRT6 in the SCC13 human line enhanced proliferation in vitro 288 
(Extended Data Fig. 7b), a phenotype inhibited by DCA. We next assessed whether 289 
SIRT6 inhibition could impair human tumor growth in vivo. For this purpose, we took 290 
advantage of an in vivo model where the tumor cells are co-injected with tumor 291 
associated fibroblasts (TAFs) and human primary keratinocytes (HPKs). Strikingly, 292 
SIRT6 knockdown in SCC13 cells significantly increased tumor growth in vivo 293 
(Extended Data Fig. 7c-e).  294 
Enhanced antioxidative response in glycolytic, CD34+ TPCs 295 
We then sought to directly analyze metabolite levels of CD34+ TPCs from in vivo 296 
tumors by utilizing Matrix-Assisted Laser Desorption/Ionization Fourier Transform Ion 297 
Cyclotron Resonance Mass-Spectrometry Imaging (MALDI FT-ICR MSI), which 298 
provides direct evidence about metabolic characteristics of TPCs20,21. We used high 299 
spatial (25um) and spectral resolution to map the metabolic profiling directly on 300 
frozen tumor sections, preserving their structure and histology. A global view of the 301 
whole tumors using this cutting-edge technique already distinguish clear metabolic 302 
heterogeneity (Extended Data Fig. 8a-b); t-Distributed Stochastic Neighbor 303 
Embedding (t-SNE) analysis of all MALDI-MSI peaks along with H&E staining of the 304 
same tissue sections created “metabolic images” with almost anatomic precision, in 305 
both its ability to separate tumors from adjacent tissues, and to depict metabolic 306 
heterogeneity within each tumor. To identify TPCs within these tumor samples, 307 
neighboring sections were stained with CD34, as a TPC marker, GLUT1, as a glycolysis 308 
marker, and Keratin10, as a differentiated suprabasal cell marker (Fig. 3f, left panels). 309 
By using a non-linear transformation algorithm to co-register the two images 310 
(MALDI-MSI and IF) from the sequential sections, we were able to appreciate relative 311 
abundance of specific metabolites in different tumor subpopulations.  312 
Glucose-6-phosphate (G6P), one of the earliest glycolysis intermediates, and 313 
citrate, one of the mitochondrial TCA cycle intermediates, both of which yielded 314 
robust signals in MALDI-MSI were used to determine relative glycolytic activity within 315 
a tumor (Fig. 3e and Extended Data Fig. 8c-g). In general, signals from G6P and 316 
citrate showed weak correlation value (below 0.3). Importantly, mean abundance (or 317 
intensity) of G6P was significantly higher in CD34+ cells, while that of citrate was 318 
significantly lower in CD34+ cells when compared to CD34- cells (Extended Data Fig. 319 
8c-g), strongly indicating increased glycolytic activity in CD34+ TPCs compared to 320 
non-TPCs. In this regard, reduced glutathione levels were much higher in CD34+ cells 321 
(Fig. 3f), consistent with what we observed in highly glycolytic cells by in vitro 322 
metabolite profiling, further strengthening our finding that TPCs specifically increase 323 
glycolysis and PPP for glutathione generation. To functionally assess whether 324 
glycolytic TPCs exhibit antioxidant properties, we checked the cellular redox state by 325 
using malonyldialdehyde (MDA), a marker of lipid peroxidation, along with SOX2, a 326 
TPC marker, in Sirt6-deficient skin tumors. Significantly, the two markers exhibited a 327 
mutually exclusive staining pattern, further indicating that an important reason for 328 
the metabolic rewiring in TPCs is to protect against oxidative stress (Fig. 3g).  329 
 330 
scRNA-seq characterizes a subset of TPCs with higher glycolysis and antioxidant 331 
response, responsible for tumor progression 332 
Our t-SNE analysis provided evidence for metabolic heterogeneity within TPCs 333 
(Fig. 4a and Extended Data Fig. 8h). In order to determine in more detail whether 334 
indeed CD34+ TPCs exhibit metabolic heterogeneity, we took advantage of single cell 335 
RNA sequencing (scRNA-seq). Dimensionality reduction analyses using both UMAP 336 
(Uniform Manifold Approximation and Projection) and t-SNE, and principal 337 
component analysis separated TPCs of the WT2 sample from all the other TPCs, 338 
indicating that TPCs of the WT2 are qualitatively different from those of the other 339 
three (Extended Data Fig. 9a-d). Based on tumor size and TPC enrichment, the WT2 340 
sample was the smallest and the least aggressive tumor, suggesting that this tumor 341 
was likely regressing (as we observed with most of the WT tumors), and thus we 342 
decided to exclude TPCs of WT2 in the analysis.  343 
Dimensionality reduction analyses of TPCs from the other three samples showed 344 
that TPCs of each sample nicely mixed together regardless of sample identity 345 
(Extended Data Fig. 9e-f), generating four distinct clusters among TPCs with 346 
differentially expressed marker genes (Fig.4b-c, and Supplementary Table 6). Analysis 347 
of Stemness and pro-differentiation program (see gene lists in Supplementary Table 348 
7) revealed that two distinct clusters, cluster I and IV, showed the highest stemness 349 
score and the lowest pro-differentiation score at comparable levels, implying that 350 
these are the most stem-like cells (Fig. 4d and Extended Data Fig. 9g-h). Based on 351 
gene expression, cluster III might represent contamination of differentiating, CD34low 352 
cells during the prospective isolation by FACS, showing clearly less stemness markers 353 
and higher pro-differentiation scores with Sprr1a/b expression (Fig. 4c-d and 354 
Extended Data Fig. 9g-h). We then compared cluster I and IV, separated by 355 
differences in their whole transcriptome while presenting similar stemness features. 356 
Remarkably, even within these two seemingly identical stem cell clusters (based on 357 
stem cell markers), cluster I exhibited significantly higher expression of genes 358 
involved in glycolysis, PPP, antioxidant response and glutathione metabolism 359 
compared to cluster IV (Fig. 4e; see gene lists in Supplementary Table 7), defining, 360 
with unprecedented resolution, metabolically distinct subsets within bona fide TPCs. 361 
Notably, trajectory analysis in a pseudotime scale strongly suggests that even though 362 
cells in the cluster IV may represent the earliest progenitors in SCC, cells in the 363 
cluster I, equally stem-like as in the cluster IV, could be the major contributors to 364 
aggressive SCC, in part due to their high glycolytic metabolism and ability to 365 
generate glutathione (Extended Data Fig. 9i-j). 366 
 367 
Redox regulation is critical for TPC enrichment and tumor progression 368 
In order to define whether increase GSH plays a functional role in TPCs, we 369 
administered an antioxidant, N-acetyl-cysteine to animals treated with DCA in vivo. 370 
Strikingly, depleted CD34+ TPCs were completely rescued by exogenous antioxidant 371 
administration both in WT and Sirt6 cKO tumors (Fig. 4f and Extended Data Fig. 10a). 372 
To confirm these results, we grew in vitro WT and shSIRT6 SCC13 cells in suspension, 373 
an approach that select for cancer stem cell activity, as analyzed by tumorsphere 374 
formation. Indeed, we saw a 4-fold increase in tumorspheres in shSIRT6 cells, a 375 
phenotype abolished by DCA treatment, and fully rescued upon addition of NAC (Fig. 376 
4g and Extended Data Fig. 10b).  377 
Lastly, we took advantage of a dataset from a recent single cell transcriptomic 378 
analyses of ten different human HNSCC samples22, and assessed glycolysis and 379 
antioxidant response gene expression. Highly glycolytic tumors (as defined by a 380 
“glycolysis score”, see Methods) exhibit a robust co-expression signature of 381 
antioxidant response genes (as defined by an “antioxidant gene score”) (Fig. 4h and 382 
Extended Data Fig. 10c-d). This positive correlation seems more obvious in the 383 
classical subtype of HNSCC, but not much in the atypical or basal subtypes of 384 
HNSCC that barely express glycolytic genes (Extended Data Fig. 10c-d). Furthermore, 385 
at a single cell transcriptome level within each classical subtype of HNSCC (MEEI20 & 386 
MEEI6), the relationship between glycolysis and antioxidant response gene expression 387 
showed a significant positive correlation (Fig. 4h). These analyses from this 388 
independent human RNA-seq data further strengthen our findings that increased 389 
glycolysis and thus enhanced antioxidant response may promote squamous cell 390 
carcinogenesis, especially through TPCs.  391 
 392 
DISCUSSION 393 
The Warburg effect is considered a late adaptation of rapidly proliferating 394 
advanced tumors, yet several descriptive studies indicated that such adaptation may 395 
occur early, with increased glycolysis and its branched metabolic pathways (e.g. 396 
serine/glycine metabolism) shown to be important specifically in tumor-initiating cells 397 
in lung, brain, and breast cancer models23,2425-27. In this study, using both genetically 398 
engineered mouse models and human SCC lines where glycolytic metabolism was 399 
manipulated, we provide direct evidence for a driving role of glycolysis in TPCs, a 400 
phenotype regulated at least in part by epigenetic mechanisms. As such, our data 401 
represents the first comprehensive analysis that metabolic reprogramming to 402 
increase glycolysis is critical for nucleotide biosynthesis and antioxidative functions in 403 
TPCs, thus identifying TPCs as the cell-of-origin for the Warburg effect in SCC. 404 
Importantly, despite exhibiting a Warburg phenotype (increased glucose uptake, and 405 
increased glycolytic flux towards the PPP and lactate production), they appeared to 406 
maintain robust mitochondrial respiration, something that has been appreciated in 407 
several other cancer types28. 408 
In cutaneous SCC, quiescent, TGFβ-responding SCC stem cells have an increased 409 
expression of genes in glutathione metabolism and redox balance, providing cisplatin 410 
resistance and tumor recurrence18. In our study, we discovered that a subpopulation 411 
of highly proliferating CD34+ TPCs showed an augmented antioxidant response and 412 
nucleotide biosynthesis via increasing glycolysis, defining a metabolic mechanism to 413 
explain the ability of these cells to drive tumorigenesis. Recent studies have shown 414 
that both quiescent and proliferative TPCs, regardless of their proliferation states, 415 
exhibit elevated gene expression of the antioxidant response genes, including 416 
glutathione metabolism genes, though most observations were in vitro, lacking in 417 
vivo relevance and evidence from direct measurements of metabolites19. Our study 418 
defined a subset of TPCs as exhibiting increased GSH and provided strong in vivo 419 
data for the importance of increased glycolysis in generating glutathione and 420 
defending against oxidative stress. We further discovered a unique “metabolic 421 
heterogeneity” within TPCs, indicating that only a defined (previously unknown) 422 
subpopulation of CD34+ TPCs acquires metabolic adaptations that could drive 423 
tumorigenesis. Our studies add metabolism to the large list of heterogeneous traits 424 
that have emerged in recent years in cancer cells29. These results may open a new 425 
therapeutic opportunity to target this specific subpopulation of TPCs in SCC by 426 
modulating glucose metabolism, in turn providing new hope for patients with these 427 
aggressive tumors for which treatment remains a challenge. 428 
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Figure Legends 536 
Figure 1. Sirt6 acts as a tumor suppressor in squamous cell carcinoma by 537 
negatively regulating aerobic glycolysis. a, DMBA/TPA-induced skin carcinogenesis 538 
protocol in Sirt6 WT or Sirt6 cKO animals. b, Tumor-free period after starting DMBA 539 
treatment in Sirt6 WT or Sirt6 cKO animals. Statistical analysis was done by log-rank 540 
test. c, Tumor size was measured at 14 weeks after DMBA treatment. Data are 541 
presented as mean ±S.D. d, Tumor progression was assessed after stopping TPA 542 
treatment (at 14 weeks post DMBA) for least 7 weeks. Fisher’s exact test was 543 
performed for statistical analysis (p<0.0001, two-sided). e, PCNA immunostaining in 544 
DMBA/TPA-treated skin tumors from Sirt6 WT or Sirt6 cKO animals. Representative 545 
images (lower panel, scale bars indicate 100µm) and quantification of PCNA+ layers 546 
from normal adjacent skin and skin tumors (upper panel). f, Schematic presentation 547 
of DCA treatment in DMBA/TPA-treated animals. DCA was administered at 7-8 weeks 548 
after DMBA treatment, in order to avoid any confounding effect of DCA on tumor 549 
initiation. g, Tumor size was measured at 14 weeks after DMBA treatment. Data are 550 
presented as mean ±S.D. h, Tumor progression was assessed after stopping TPA 551 
treatment with continuous DCA treatment. Data of the first two groups shown in 552 
Figure 1d were used again for comparison. Fisher’s exact test was performed for 553 
statistical analysis (p<0.0001, two-sided). i, GLUT1 and phospho-PDH (Ser293) 554 
immunostaining in Sirt6-deleted large papilloma samples. Scale bars indicate 100µm. 555 
Statistics, sample sizes (n) and numbers of replications are presented in Methods, 556 
‘Statistics and reproducibility’. * p<0.05, ** p<0.01, *** p<0.001 557 
Figure 2. Increased glycolysis enriches for tumor-propagating cells in vivo. a, 558 
Immunofluorescence images against GLUT1, CD34, and SOX9 in Sirt6-deficient 559 
tumors and normal epidermis. Images were acquired by a Leica SP8 white light 560 
confocal microscope. Scale bars indicate 50µm. b & c, Representative FACS plots to 561 
analyze and isolate tumor-propagating cells (α6 integrinhigh/CD34+) from Sirt6 WT or 562 
Sirt6-deleted skin tumors without DCA (b) or with DCA (c). d, DAVID pathway 563 
analysis (GOTERM_BP_DIRECT) of 397 commonly upregulated genes in TPCs from 564 
differentially expressed genes (DEGs) between TPCs and α6high/CD34- cells in each 565 
genotype. e & f, Representative gene list and corresponding fold changes in 566 
expression from Sirt6 WT or cKO TPCs and its negative counterparts (α6high/CD34-) 567 
for functional gene categories associated with each biological process. Data indicate 568 
mean. Statistics, sample sizes (n) and numbers of replications are presented in 569 
Methods, ‘Statistics and reproducibility’.  570 
Figure 3. Glycolytic TPCs uniquely upregulate glutathione metabolism via the 571 
oxidative PPP to mitigate oxidative stress. a & b, Relative enrichment of fully 572 
labeled metabolic intermediates after incubation with U-13C-glucose (a) or 1,2-13C-573 
glucose (b) at a given time point either in SIRT6 WT or H133Y overexpressing HSC2 574 
cells (26hr post doxycycline). Data are presented as mean ±S.D. c, 13C incorporation 575 
into DNA from U-13C-glucose via ribose-5-phosphate (M+5) at 24hr either in SIRT6 576 
WT or H133Y overexpressing HSC2 cells (26hr post doxycycline). Data are presented 577 
as mean ±S.D. d, A relative abundance of GSH and a relative ratio of GSSG/GSH 578 
either in control (shCtrl) or SIRT6 knockdown (shSIRT6) SCC13 cells 3 days post 579 
doxycycline. Data is from at least two biological replicates (n=2 for shCtrl and n=3 580 
for shSIRT6). Data are presented as mean ±S.E.M. e, Co-registration images (the left 581 
two) of G-6-P and citrate on top of immunofluorescence image (CD34 and GLUT1) in 582 
tumor 2. Overlay image (the very right) of G-6-P and citrate with a correlation value 583 
of distribution between two metabolites. Scale bars indicate 300µm f, 584 
Immunofluorescence image against CD34, GLUT1, and Keratin10 (left panels) and 585 
MALDI-MSI (glutathione) from DMBA/TPA-treated skin tumors (middle panels), and 586 
box plots to compare glutathione abundance between different tumor 587 
subpopulations (right panels). Scale bars indicate 300µm g, Immunohistochemical 588 
analysis against malonyldialdehyde (MDA), a lipid peroxidation marker and SOX2, a 589 
functional TPC marker in the same tumor samples (serially sectioned). Scale bars 590 
indicate 100µm. Statistics, sample sizes (n) and numbers of replications are presented 591 
in Methods, ‘Statistics and reproducibility’. * p<0.05, ** p<0.01, *** p<0.001 592 
Figure 4. A subset of TPCs that are glycolytic supports glutathione metabolism 593 
and antioxidant response, functionally critical for TPC enrichment and 594 
tumorigenic potential in vivo. a, A tSNE image of MALDI-MSI only with CD34+ cells 595 
b, Dimensionality reduction analysis (UMAP (resolution 0.5) and tSNE) of 596 
prospectively isolated CD34+ TPCs (1 WT tumor and 2 Sirt6 cKO tumors) c, A 597 
heatmap showing top 5 differentially expressed genes in each cluster d, Cd34 and a6 598 
integrin expression levels in UMAP graphs (the very left), and violin plots (right two) 599 
showing stemness and pro-differentiation program score in each cluster e, Violin 600 
plots showing glycolysis, pentose phosphate pathway (PPP), antioxidant response, 601 
and glutathione metabolism program score in the cluster I and IV f, Representative 602 
FACS plots to analyze and isolate tumor-propagating cells (α6 integrinhigh/CD34+) 603 
from Sirt6 WT or Sirt6-deleted skin tumors with DCA (top) or with DCA and NAC 604 
(bottom). DCA treatment plots in the top are the same as the ones in Fig. 2C. g, The 605 
number of tumorspheres at day 10 in SCC13 cells in indicated conditions. Data 606 
indicate mean ±S.E.M.  h, Scatter plot of glycolysis score and antioxidant gene 607 
signature score in single cells of two classical subtypes of HNSCC with a linear 608 
regression. Pearson correlation coefficients are 2.7e-48 for MEEI20 and 6.2e-06 for 609 
MEEI6, respectively. Statistics, sample sizes (n) and numbers of replications are 610 
presented in Methods, ‘Statistics and reproducibility’. * p<0.05, ** p<0.01, *** 611 
p<0.001 612 
METHODS 613 
Mice and chemical-induced skin carcinogenesis Mice were housed in pathogen-614 
free facilities. All experiments were conducted under the protocol 2019N000111 615 
approved by the Subcommittee on Research Animal Care at Massachusetts General 616 
Hospital. Mice were maintained as a highly pure C57BL/6 background (> 96%). 617 
Unless indicated, all animals were maintained under a standard diet (Prolab Isopro 618 
RMH 3000, Cat. #0006972). Data presented include both male and female mice. Sirt6 619 
F/F conditional strain13  were crossed with the K14-cre strain (Jackson laboratory). For 620 
flow cytometry analysis, these animals were further crossed with ROSA26-LSL-EYFP 621 
(Jackson laboratory). Two days after shaving their back hairs, 8-week-old mice were 622 
subject to a one time DMBA (Sigma, 200 nmol in acetone) treatment followed by 623 
TPA (Sigma, 20 nmol in acetone) treatment three times a week for 14 weeks. After 14 624 
weeks of DMBA/TPA treatment, some mice were kept without TPA treatment for at 625 
least 7 weeks to observe tumor progression. The appearance and the number of 626 
tumors were closely monitored twice a week. Any visible mass that was more than 1 627 
mm in size and existed for more than a week was considered as a tumor for onset 628 
and counting numbers of tumors. Some of the DMBA/TPA-treated animals were 629 
administered with DCA (Acros Organics, 5 g/L) and/or N-acetyl cysteine (Sigma, 1g/L) 630 
in their drinking water. N-acetyl cysteine containing water was changed every week 631 
due to stability of this drug in aqueous solution. Blood from tail vein was collected 632 
into EDTA-coated tubes. Plasma was separated by centrifugation (15000 rpm, 10min, 633 
4°C) for further analysis.  634 
For the analysis and prospective isolation of TPCs, we generated K14-cre+; Sirt6 F/F; 635 
ROSA26-LSL-YFP (Sirt6 cKO) animals as well as Sirt6 WT (K14-cre+; Sirt6 +/+; 636 
ROSA26-LSL-YFP) animals to specifically isolate YFP+ epithelial cells by FACS. In 637 
addition, because we had difficulty obtaining sizable WT tumors with the previous 638 
DMBA/TPA treatment protocol, we modified the protocol by treating mice with TPA 639 
for more than 24 weeks in order to obtain sufficient number of cells to perform sub-640 
population analysis. 641 
Humane Endpoint: for all tumors' assays, animals were euthanized according to 642 
IACUC protocol (tumors reached 20mm, ulcerated mass, or loss of 15% weight).  643 
Human data sets SIRT6 expression and copy number, and glycolytic gene expression 644 
data were obtained from the Oncomine30 and the Cancer Cell Line Encyclopedia31. 645 
SIRT6 copy number and the corresponding survival of each patient data were 646 
obtained from the The Cancer Genome Atlas32. A Kaplan-Meier plot was made and 647 
the log-rank p-value was calculated for the SIRT6 copy number in the TCGA HNSC 648 
samples. TCGA HNSC clinical information was downloaded from the TCGA data 649 
matrix access portal (http://cancergenome.nih.gov) during December 2015 and 650 
GISTIC2 processed copy number data for TCGA HNSC was downloaded from the 651 
Broad Institute (http://gdac.broadinstitute.org) during April 2015. Follow-up clinical 652 
data files were merged with the original clinical data file to ensure that the most up-653 
to-date patient follow-up information was used for survival analysis. The Kaplan-654 
Meier survival plot and the log-rank p-value were generated using R with the 522 655 
TCGA HNSC primary tumor samples with both clinical data with a death event or at 656 
least six months of follow-up and GISTIC2 copy number data available. Kaplan-Meier 657 
plots used overall survival with death from any cause as the endpoint and patients 658 
still alive at last follow-up were censored at last follow-up time. Samples were split 659 
into 5 groups based upon the GISTIC2 data for SIRT6 in the 660 
all_thresholded.by_genes.txt results file (a gene-level table of discrete amplification 661 
and deletion indicators at for all samples). Within the GISTIC2 table, values of 0 662 
means no amplification or deletion above the threshold (0.1) while positive numbers 663 
represent amplifications and negative numbers represent deletions (1 means 664 
amplification above the amplification threshold, 2 means amplifications larger than 665 
any arm-level amplifications observed for the sample, -1 represents deletion beyond 666 
the threshold, -2 means deletions greater than the minimum arm-level deletion 667 
observed for the sample). 668 
Human tumor sample analysis Primary HNSCC tumors and newborn baby foreskins 669 
(used as normal tissue in this study) analyzed in this study were collected following 670 
institutional IRB approval. The collection and use of discarded, de-identified tissue 671 
was reviewed and approved by the Dana-Farber/Harvard Cancer Center IRB (Protocol 672 
#03-204). Briefly, tissues were fixed in formalin followed by ethanol and paraffin 673 
embedded followed by serial sectioning onto slides for IHC.  674 
Histology and immunostaining Mouse back skin and skin tumors were harvested, 675 
submitted for histological examination, and analyzed in a blinded fashion by a 676 
pathologist (Dr. Roderick Bronson) at the DF/HCC Research Pathology Core. Tissue 677 
samples were fixed overnight in 10% buffered formalin, and then embedded in 678 
paraffin and sectioned 5μm thickness by the DF/HCC Research Pathology Core. 679 
Hematoxylin and eosin staining was performed using standard methods. 680 
Immunohistochemistry was performed as previously described with modifications33. In 681 
brief, deparaffinization, rehydration, and antigen retrieval were performed in 682 
unstained slides with Trilogy solution (Cell Marque). Slides were incubated for 20min 683 
with 4% H2O2 at RT to block endogenous peroxidase activity and rinsed twice with 684 
water. Sections were blocked with 10% goat serum (Cell signaling) in TBS-0.1% tween 685 
20 for an hour at RT, and then incubated overnight with primary antibodies at 686 
4°C.The following primary antibodies were used: anti-SIRT6 (Cell Signaling, #12486) 687 
1:50 for human tissues and 1:100 for mouse tissues, anti-GLUT1 (Abcam, ab40084) 688 
1:200 for human and mouse tissues, anti-PCNA (Santa Cruz, sc-56) 1:500 for mouse 689 
tissues, anti-phospho-PDH (Abcam, ab92696) 0.1 μg/ml for mouse tissues, anti-MPC1 690 
(Sigma, HPA045119) 1:100 for mouse tissues, anti-SOX2 (Abcam, ab92424) 1:50 for 691 
mouse tissues, anti-MDA (Abcam, ab6463) 1:1000 for mouse tissues, and anti-CD34 692 
(BD sciences, 553731) 1:50 for mouse tissues. Slides were washed three times for 693 
10min each in TBST and incubated with biotinylated secondary antibodies (1:200, 694 
Vector Laboratories) in blocking solution for 45min at RT, followed by signal 695 
detection using Vectastain ABC kit (Vector Laboratories) and DAB substrate kit 696 
(Vector Laboratories). Counterstaining was performed with hematoxylin. Stained 697 
slides were photographed with an Olympus DP72 microscope or a Leica DM1000 698 
microscope. Immunofluorescence staining was performed as previously described 699 
with modifications33. Briefly, deparaffinization, rehydration, and antigen retrieval were 700 
performed in unstained slides with Trilogy solution (Cell Marque). Sections were 701 
blocked with 5% goat serum (Cell signaling), 1% BSA (Sigma), and 0.2% gelatin 702 
(Sigma) in PBS-0.1% triton-x for an hour at RT, and then incubated overnight with 703 
primary antibodies at 4°C. The following primary antibodies were used: anti-GLUT1 704 
(Abcam, ab40084) 1:200 for mouse tissues, anti-CD34 (BD sciences, 553731) 1:50 for 705 
mouse tissues, anti-SOX9 (Millopore, AB5535) 1:2000 for mouse tissues, anti-706 
H3K56Ac (Abcam, ab76307) 1:500 for mouse tissues, anti-Keratin 5 (Covance, PRB-707 
160P) 1:1000 for mouse tissues, and anti-Keratin 10 (Covance, PRB-159P) 1:1000 for 708 
mouse tissues. Slides were kept in dark containers. Samples were washed three times 709 
for 10min each in TBST and incubated with secondary antibodies for 2hr at RT. The 710 
following secondary antibodies were used: anti-rabbit, anti-mouse, and anti-rat 711 
conjugated to AlexaFluor488 (Molecular Probe, 1:500-1:1000), AlexaFluor595 712 
(Molecular Probe 1:500-1:1000), AlexaFluor647 (Molecular Probe 1:400-1:1000), and 713 
rhodamin red-X (Jackson ImmunoResearch, 1:500-1:1000). Stained slides were 714 
mounted in the mounting reagent (Vector lab, H-1200) containing DAPI for nuclei 715 
staining. Pictures were obtained using a Leica SP8 white light confocal microscope or 716 
a Nikon Eclipse Ni-U fluorescence microscope. Quantification of positive/negative 717 
cells was done manually using ImageJ. 718 
Real time RT-qPCR analysis Total RNA was extracted with the TriPure isolation 719 
reagent (Roche) as described by the manufacturer. For RNA isolation from mouse 720 
skin or tumor samples, additional RNA clean up procedure was performed with the 721 
RNeasy Protect Mini kit (Qiagen). cDNA synthesis and Real-time PCR were done as 722 
previously described14. In brief, isolated RNA was reverse transcribed by using the 723 
QuantiTect Reverse Transcription kit (Qiagen). Real-time PCR was performed using 724 
SYBR green master mix (Roche) with the final volume of 12.5 μl per reaction in 725 
LightCycler 480 detection system (Roche). Data were presented as relative mRNA 726 
levels normalized to the β -actin expression level in each sample. The primer 727 
sequences are listed in Supplementary Table 8. 728 
Mouse tumor cell isolation and fluorescence-activated cell sorting (FACS) Mice 729 
bearing skin tumors were euthanized and the tumors were collected on ice. Each 730 
tumor was cut into small pieces and incubated with 0.5% trypsin (diluted in 731 
keratinocyte serum-free medium, Gibco) on a horizontal shaker at 37°C for 1.5 hr. 732 
Using an 18G syringe, digested tumor cells were physically isolated into a single cell 733 
suspension. The trypsin was inactivated by adding chelexed FBS. After serial filtering 734 
with 70μm and 40μm strainers (BD sciences), tumor cells were centrifuged at 1200 735 
rpm, 4°C for 10 min. Cell pellets were resuspended with PBS containing 4% chelexed 736 
FBS and then transferred into FACS tubes with a 40μm filter. The following 737 
fluorophore-conjugated antibodies were used: anti-CD34-BV421 (BD sciences, 738 
562608, 1:50) and anti-CD49f-PE (eBiosciences, 12-0495-81, 1:200), anti-GLUT1-A647 739 
(Abcam, ab195020, 1:100). Propidium iodide (Sigma, P4864, 1:1000) or Zombie NIR 740 
fixable viability dye (Biolegend, 423105, 1:100) were used to negatively select live 741 
cells. Proper isotype controls, single color controls, and FMO controls were used in 742 
every experiment to set up optimal compensation and gates. Cells were analyzed and 743 
sorted using a FACSAria II (BD). Obtained data were analyzed by FlowJo. An 744 
exemplary gating strategy is described in Supplementary Information Figure 1. 745 
RNA preparation and RNA sequencing. Following FACS isolation of two different 746 
tumor sub-populations (α6high/CD34+ and α6high/CD34-) from at least two 747 
independent skin tumors obtained from Sirt6 WT and Sirt6-deleted animals, sorted 748 
tumor cells were directly collected into RNA isolation buffer provided in the kit 749 
(Clontech, #740902.50). RNA isolation was conducted by the manufacturer’s 750 
instruction. Library construction was performed using the SMART-Seq v4 Ultra Low 751 
Input RNA kit to produce cDNA (Clontech, #634888). The total RNA input amount for 752 
this kit was 10 ng total.  8 cycles of PCR were performed for PCR amplification.  Post 753 
cDNA construction, the samples were validated using an Agilent 2100 Bioanalyzer 754 
and Agilent's High Sensitivity DNA kit. Prior to generating the final library for Illumina 755 
Sequencing, the Covaris AFA system is used to shear cDNA resulting in a 200-500 bp 756 
size range. Sheared libraries are validated using Agilent 2100 Bioanalyzer and 757 
Agilent's High Sensitivity DNA kit. Quantification was completed by using a Qubit 4 758 
fluorometer (Invitrogen) using the Qubit RNA HS Assay kit. Generation of the final 759 
library was completed by using Low Input Library Prep Kit v2 (Clontech, #634899). 760 
The cDNA input amount was 10 ng total. 7 cycles of PCR were performed for PCR 761 
amplification. Post library construction, the samples were validated using the 2200 762 
Tapestation System and High Sensitivity D1000 ScreenTape kit. Libraries were 763 
quantified using the Library Quantification kit (Kapa Biosystems, #KK4828) and the 764 
BioRad CFX96 instrument. Each lane of sequencing was pooled into a 6-plex (6 765 
samples per lane) with unique barcodes. Pooled libraries were also quantified using 766 
the Kapa Biosystems Library Quantification kit (#KK4828) and the BioRad CFX96 767 
instrument. These pools were then denatured to 16pM with 1% phix and sequenced 768 
on the Illumina HiSeq2000 instrument, producing approximately 30 million paired-769 
End 50bp reads per sample. 770 
RNA sequencing analysis STAR aligner34 was used to map sequencing reads to the 771 
mouse reference transcriptome (mm9 assembly).  Read counts over transcripts were 772 
calculated using HTSeq v.0.6.035 based on a current Ensembl annotation file for 773 
NCBI37/mm9 assembly. Differential expression analysis was performed using EdgeR36, 774 
genes were classified as differentially expressed based on the cutoffs of at least 2-775 
fold change. Analysis of enriched functional categories among detected genes was 776 
performed using DAVID37. 777 
Cell lines and cell culture SCC13 cells (a gift from Paolo Dotto, MGH Cutaneous 778 
Biology department, USA) were grown in keratinocyte serum-free medium (K-SFM, 779 
Gibco) supplemented with EGF (epidermal growth factor) and bovine pituitary extract 780 
based on the manufacturer’s instruction. HSC2 cells (a gift from Cyril Benes, MGH 781 
Cancer Center, USA) were grown in DMEM/F-12 medium with 10% Tet system 782 
approved FBS (Clontech) and 1% penicillin (100 U/ml)/streptomycin (100 U/ml) 783 
(Gibco). Human primary keratinocytes were obtained from CellnTec and were grown 784 
in CnT-PR medium (CellnTec) supplemented with 1% penicillin (100 785 
U/ml)/streptomycin (100 U/ml) (Gibco). Human tumor-associated fibroblasts (a gift 786 
from Salvador Aznar Benitah, IRB, Spain) were grown in DMEM medium 787 
supplemented with 10% FBS (Sigma), Insulin-Transferrin-Selenium reagent (Gibco), 788 
and 1% penicillin (100 U/ml)/streptomycin (100 U/ml) (Gibco). All cells were cultured 789 
and maintained at 37°C under 5% CO2. Human primary keratinocytes (Cat. #HPEKp, 790 
CellIn Tec), were passaged with accutase (Gibco) and were used within four passages. 791 
All the other cell lines were passaged by trypsinization.  792 
Constructs and viral infection Human pTripZ-shSIRT6 (Dharmacon RHS4740) and 793 
negative control shRNA vector were kind gifts from David Lombard (University of 794 
Michigan, USA). pMSCV-luc-PGK-Neo-IRES-eGFP construct was a kind gift from 795 
Martina Weissenboeck (IMP, Austria). pLVX-Tet-On was obtained from Clontech. 796 
Human pRetro-SIRT6 WT and pRetro-SIRT6 H133Y were previously described17. Viral 797 
particles containing the above-mentioned constructs were generated using either 798 
lentiviral (pCMV-d8.9) or retroviral (pCL-ECO) packaging plasmids with pCMV-VSV-G 799 
(Addgene) in 293T cells. Virus-containing supernatant was filtered in 0.45 μm filter 800 
and added into target cell lines with 8 μg/ml polybrene. For infection of SCC13 cells, 801 
filtered virus-containing supernatant was ultra-centrifuged at 20,000 g, 4°C for 2 hr 802 
to concentrate into a very small volume (~200 μl) and about 5 μl of virus concentrate 803 
was used for infection of SCC13 cells. For efficient infection, 6-well plates with SCC13 804 
cells added virus concentrate and polybrene were centrifuged at 2,250 rpm, 32°C for 805 
1 hr and virus-containing media were immediately replaced by regular K-SFM. The 806 
next day, cells were selected in 2 μg/ml of puromycin, or 1.4 mg/ml of neomycin for 807 
SCC13 cells, or in 1.5 μg/ml puromycin, or 0.5 mg/ml of neomycin for HSC2 cells for 808 
at least a week and the pooled populations were used for various experiments. 809 
SCC13 cells with dox-inducible pTripZ constructs were treated with 1 μg/ml 810 
doxycycline for at least 3 days and HSC2 cells with dox-inducible pRetro constructs 811 
were treated with 100 ng/ml doxycycline for 26 hr unless otherwise indicated.  812 
Western blot analysis Whole cell lysates/chromatin fractions were prepared and 813 
western blot analysis was performed as previously described12. In brief, for chromatin 814 
extraction, cell pellets were lysed in buffer containing 10mM HEPES pH7.4, 10mM 815 
KCl, 0.05% NP-40 supplemented with a protease inhibitor cocktail (Complete EDTA-816 
free, Roche Applied Science), 5 μM TSA, 5mM sodium butyrate, 1mM DTT, 1mM 817 
PMSF, and 0.2mM sodium orthovanadate. After incubation for 20min on ice, the 818 
lysates were centrifuged at 14,000 rpm, 10min at 4 °C. The supernatant was removed 819 
(cytosolic fraction) and the pellet (nuclei) was acid-extracted using 0.2N HCl by 820 
incubating 20min on ice. The lysate was further centrifuged at 14,000 rpm, 10min at 821 
4 °C. The supernatant was neutralized in 1M Tris-HCl pH 8. Protein concentration was 822 
determined by Biorad protein assay. Western blots were performed using 8-15% 823 
gradient gels (Biorad). Primary antibodies were used as follows: anti-SIRT6 (Cell 824 
signaling #12486), anti-H3K9Ac (Millipore, 07-352), anti-H3K56Ac (Abcam, ab76307), 825 
anti-total H3 (Abcam, ab1791), anti-GLUT1 (Abcam, ab40084), anti-PDK1 (Cell 826 
signaling, #3820), anti-LDHA (Cell signaling, #2012S), anti-phospho-PDH (Abcam, 827 
ab92696), and anti-β-actin (Sigma, A5316). All uncropped and unprocessed scans are 828 
available in Source Data Figures 1-4. 829 
Glucose uptake assay In SCC13 cells, cells were plated in duplicates on 6-well plates 830 
(2.5*105 cells/well) in culture medium a day before the experiment. Media containing 831 
2-NBDG (Invitrogen, 100 μM) were added for 2 hr. Fluorescence was measured in 832 
FACSAria II. Obtained data were analyzed by FlowJo. After proper compensation, 833 
geometric mean value was normalized by its negative control (without 2-NBDG) of 834 
each group.  835 
Glycolytic capacity Cells were plated into XFe96 cell culture microplates (Seahorse 836 
Bioscience) a day before the experiment. Media were replaced in the Seahorse 837 
microplates with assay medium supplemented with 2 mM L-glutamine (Gibco), pH 838 
7.35 ± 0.05 for glycolysis stress test. The plate was incubated in a CO2-free incubator 839 
for 1 hr at 37°C. For glycolysis test, 10 mM of glucose, 2 μM of oligomycin, 100 mM 840 
of deoxyglucose were sequentially injected. ECAR was measured in every well based 841 
on the instrument’s protocol. Experiments were run using an XFe96 analyzer and raw 842 
data were normalized by cell number calculated with Cyquant cell proliferation assay 843 
kit (Thermo scientific). 844 
Chromatin immunoprecipitation Chromatin immunoprecipitation followed by RT-845 
qPCR was performed as previously described38 with H3K9Ac (Millipore, 07-352). In 846 
brief, SCC13 cells were crosslinked with 1% formaldehyde/PBS for 15miin at RT, 847 
followed by quenching with 0.125M glycine. After washing twice with PBS, cells were 848 
collected in RIPA buffer, and then were sonicated to generate DNA fragments of 849 
approximately 500 bp in size. About 200ug of pre-cleared protein extract was used 850 
for immunoprecipitation overnight (>12hr) at 4 °C using protein A/G agarose beads 851 
(Santa Cruz, sc2003). Washed samples were eluted by incubation at 65 °C for 10 min 852 
with 1% SDS, and crosslinking was reversed by incubation at 65 °C for 6 hr with 853 
200mM NaCl. DNA was purified using the QIAquick spin kit (Qiagen) and assessed by 854 
real-time qPCR using the LightCycler 480 system (Roche). The primers’ sequences are 855 
listed in Supplementary Table 9.  856 
Isotope tracing experiment HSC2 Cells were maintained with doxycycline for 26hr, 857 
at which point intracellular metabolites were collected after adding labeled media at 858 
different time points. Glucose-free DMEM/F-12 medium (US biological) was 859 
supplemented with 10% dialyzed FBS, 17.5 mM of U-13C-glucose or 1,2-13C-glucose 860 
(Cambridge isotope labs), and 15 mM HEPES.  SCC13 cells were maintained with 861 
doxycycline for 3 days, at which point intracellular metabolites were collected after 862 
adding labeled media at different time points. Keratinocyte serum-free medium 863 
(Gibco) was supplemented with 5.8 mM of U-13C-glucose (Cambridge isotope labs). 864 
At different time points after replenishing labeled media, media from biological 865 
triplicates (in 6-well plate) was fully aspirated. Each well was washed with 0.9% ice-866 
cold NaCl twice and 1 ml of 80% (v/v) methanol was added at dry ice temperature. 867 
After vigorous vortexing, insoluble material in lysates was centrifuged at 16,000 g, 868 
4°C for 10min. The supernatant was transferred and the solvent was evaporated 869 
using a SpeedVac. Samples were stored at -80°C until analyzed. 870 
Metabolite profiling by LC-MS Metabolite profiling and isotope tracing LC/MS 871 
analyses were conducted on a QExactive bench top orbitrap mass spectrometer 872 
equipped with an Ion Max source and a HESI II probe, which was coupled to a 873 
Dionex UltiMate 3000 HPLC system (Thermo Fisher Scientific, San Jose, CA). External 874 
mass calibration was performed using the standard calibration mixture every 7 days. 875 
Typically, samples were reconstituted in 100 μL water and 2 μL were injected onto a 876 
SeQuant® ZIC®-pHILIC 150 x 2.1 mm analytical column equipped with a 2.1 x 20 877 
mm guard column (both 5 mm particle size; EMD Millipore). Buffer A was 20 mM 878 
ammonium carbonate, 0.1% ammonium hydroxide; Buffer B was acetonitrile. The 879 
column oven and autosampler tray were held at 25°C and 4°C, respectively. The 880 
chromatographic gradient was run at a flow rate of 0.150 mL/min as follows: 0-20 881 
min: linear gradient from 80-20% B; 20-20.5 min: linear gradient form 20-80% B; 882 
20.5-28 min: hold at 80% B. The mass spectrometer was operated in full-scan, 883 
polarity-switching mode, with the spray voltage set to 3.0 kV, the heated capillary 884 
held at 275°C, and the HESI probe held at 350°C. The sheath gas flow was set to 40 885 
units, the auxiliary gas flow was set to 15 units, and the sweep gas flow was set to 1 886 
unit. MS data acquisition was performed in a range of m/z = 70–1000, with the 887 
resolution set at 70,000, the AGC target at 1x106, and the maximum injection time at 888 
20 msec. An additional scan (m/z 220-700) in negative mode only was included to 889 
enhance detection of nucleotides. Relative quantitation of polar metabolites was 890 
performed with XCalibur QuanBrowser 2.2 (Thermo Fisher Scientific) using a 5ppm 891 
mass tolerance and referencing an in-house library of chemical standards. For stable 892 
isotope tracing analyses, data were corrected for natural abundance39. Metabolite 893 
pool sizes of the above-mentioned metabolites are described in Supplementary table 894 
5.  895 
Lactate measurement by GC-MS Ice-cold methanol was added into 5 ul of plasma 896 
from tail vein blood, vigorously vortexed at 4°C for 10min, followed by centrifugation. 897 
The supernatant was transferred and the solvent was evaporated using a SpeedVac. 898 
Samples were stored at -80°C until analyzed.  Derivatization and measurement on 899 
the GC-MS was done as previously described40. In brief, polar metabolites were 900 
derivatized with 20mg/ml methoxyamine in pyridine for 90min at 37°C and 901 
subsequently with N-(tert-butyldimethylsilyl)-N-methyl-trifluorosilane and 1% tert-902 
butyldimethylchlorosilane for 60min at 60°C. Metabolite levels were then measured 903 
with a 5977B GC system (Agilent Technologies). The raw ion chromatograms were 904 
extracted to determine metabolite levels using a custom Matlab M-file41.  905 
ROS measurement Cells were plated in duplicates on 12-well plates (1*105 cells/well) 906 
in culture medium. After 3 days in the presence or absence of doxycycline (1 μg/ml), 907 
cells were trypsinized, centrifugated, and resuspended in the media. Cells were 908 
incubated with CellROX deep red (Invitrogen) for 30min at 37°C. Fluorescence was 909 
measured in LSRII (BD). Obtained data were analyzed by FlowJo. 910 
Proliferation assay SCC13 cells were pretreated with doxycycline (1 μg/ml) for at 911 
least 3 days before plating cells. Cells were plated in triplicates on 6-well plates 912 
(1*104 cells per well) in culture medium with doxycycline in the presence or absence 913 
of DCA. Adherent cells were trypsinized and counted by trypan-blue exclusion at 2, 3, 914 
5 days later.  915 
Apoptosis assay Cells were plated in duplicates on 12-well plates (2.5*104 cells/well) 916 
in culture medium. After 4 days in the presence of doxycycline (100 ng/ml), all the 917 
floating and adherent cells were collected and stained with Annexin V-FITC (BD 918 
sciences) and PI (Sigma) to analyze cell death in Accuri (BD). Obtained data were 919 
analyzed by FlowJo. 920 
Skin xenotransplantation assay and bioluminescence imaging SCC13 shCtrl or 921 
shSIRT6 cells were stably transduced with retrovirus containing pMSCV-luc-PGK-Neo-922 
IRES-eGFP. After neomycin selection (1.4 mg/ml), infected cells were further sorted 923 
with GFP using a FACSAria II (BD) and sorted GFPhigh cells were cultured before the 924 
experiment. 4,000 cells of SCC13 shCtrl or shSIRT6 cells, 1,000 cells of human primary 925 
keratinocytes, and 500 cells of tumor-associated fibroblasts were prepared and mixed 926 
immediately before injection. Mixed cells were injected after inserting a silicone 927 
chamber (Renner GmbH) in the back skin of NSG mice (Jackson laboratory) under 928 
avertin anesthesia. Doxycycline (200 μg/ml) was administered in the drinking water 929 
and was replaced every week due to its light sensitivity. After 8 days, the silicone 930 
chamber was removed from the back skin of the mice under avertin anesthesia and 931 
several sutures were made to aid the wound healing process. All the surgical 932 
procedures were performed in the aseptic hood of the pathogen-free facility. Every 933 
mouse was singly housed due to the small open-wounded area after silicone 934 
chamber removal. From day 23, all the mice were subject to bioluminescence 935 
imaging once a week. Under isoflurane anesthesia, 300μl of D-luciferin (15 mg/ml) 936 
(RR labs Inc., San Diego, CA) was injected intraperitoneally, and the mice were 937 
imaged every 5 min after injection with a 0.5 s to 60 s exposure time with a binning 938 
of 8 and 4 on an Ami-X imaging system (Spectral Instruments Imaging, Tucson, AZ) 939 
until the total flux and maximal radiance peaked. Total flux (photons/s) and maximal 940 
radiance (photons/s/cm2/sr) were measured by Spectral Ami X (Spectral Instruments 941 
Imaging, Tucson, AZ). A region of interest (ROI) was drawn around the tumor region 942 
for each mouse as well as a background ROI outside of the mice of which was 943 
subtracted from the total flux and maximum radiance for each mouse. 944 
Humane Endpoint: for all tumors' assays, animals were euthanized according to 945 
IACUC protocol (tumors reached 20mm, ulcerated mass, or loss of 15% weight). 946 
3D tumorsphere assay 5 * 104 SCC13 cells pretreated with doxycycline for at least 3 947 
days were trypsinized and plated into 24-well ultra-low attachment plates (Corning) 948 
with DMEM/F12 media supplemented with 2% B27 (Invitrogen), 0.4% BSA (Sigma), 20 949 
ng/ml EGF (Peprotech), and 4ug/ml Insulin (Sigma). Fresh media with doxycycline 950 
were added in every 3 days. The number of tumorspheres was manually counted 951 
under a Nikon Eclipse Ni-U microscope at day 10. 952 
MALDI Mass Spectrometry Imaging (MSI) in skin tumors DMBA/TPA-treated skin 953 
tumors and adjacent skin samples were collected, snap-frozen in LN2, and stored at -954 
80°C until analysis. Samples were embedded in a solution of 2% methylcellulose for 955 
sectioning in the Microm HM550 cryostat (Thermo Scientific) at 10µm thickness. The 956 
cryo-sections were mounted in indium tin oxide (ITO) slides pre-coated with 90% 957 
CHCA (5 mg/mL) in acetonitrile for MALDI MSI and consecutive sections were 958 
mounted in regular glass slides for immunostaining. The ITO slides were then coated 959 
with 90% 9-aminoacridine (5 mg/mL in acetonitrile) using an automated matrix 960 
sprayer (TM-sprayer, HTX imaging, Carrboro, NC) under the following conditions: 4 961 
passes, 0.17 mL/min flow rate, 75°C, 10 psi nitrogen pressure, 1000 mm/min speed. A 962 
9.4T SolariX XR FT-ICR mass spectrometer (Bruker Daltonics, Billerica, MA) with a 963 
MALDI source was used to acquire spectra in negative ion mode, with a raster pixel 964 
size of 25 µm. The mass range was m/z 60-1500 with continuous accumulation of 965 
selected ions was set between m/z 100-520. A tuning mix was used for external 966 
calibration in the selected mass range. FlexImaging 5.0 was used for acquiring the 967 
images, while Scils 2019c was used for data processing.     968 
Multi-nodal images processing and integration 1) H&E and IF: The H&E and 969 
immunofluorescence images were pre-processed42 to exclude the background noise. 970 
These two imaging modalities exhibit local deformations (such as compression and 971 
tearing) due to the manual nature of the tissue sectioning process and the 972 
underlying different staining procedures. The iterative parametric-based image 973 
registration framework was used to non-linearly warp the H&E image to be spatially 974 
aligned with immunofluorescence image43. The non-linear image registration process 975 
was first initialized by Affine transformation to capture global deformations (scaling, 976 
rotation, translation, and shearing) and map the images to the same coordinate 977 
space. The non-linear transformation model of cubic B-Spline was used to model the 978 
local deformations. The cost function of mutual information has been found efficient 979 
as a similarity metric for multi-modal registration44 and it was optimized by the 980 
adaptive stochastic gradient descent algorithm45. For robustness and faster 981 
convergence, the image registration was implemented using a multi-resolution 982 
strategy that employed 8-levels of Gaussian smoothing46. The registration algorithm 983 
was implemented using the publicly available toolbox of elastix43, and eventually it 984 
yields an optimized non-linear transformation model, T .  985 
2) MALDI-MSI and H&E: The complex nature of MSI data pose challenges that hinder 986 
direct co-registration with histology. This complexity is described in terms of high 987 
dimensionality and the lack of established spatial correspondences between 988 
biochemical and anatomical images. We have adopted the t-SNE based non-linear 989 
image registration methodology developed by Abdelmoula et al.47. Briefly, the t-SNE 990 
computes pairwise similarities of the high dimensional datapoints (i.e. spectra) and 991 
non-linearly maps it into a lower dimensional embedding of 3-dimensions. The t-SNE 992 
non-linearity preserves the local similarity of the higher dimensional datapoints in the 993 
embedding space as such similar spectra are projected closely to each other whereas 994 
dissimilar ones are projected further away. The embedding features were spatially 995 
mapped to form a t-SNE image that reveals structures in which edges demarcate 996 
molecularly distinct regions. The t-SNE image was non-linearly aligned to histology 997 
using the elastix toolbox43. The registration was initialized with Affine transformation 998 
to capture linear deformation and then followed by a cubic B-Spline transformation 999 
to capture non-linear deformations. The cost function of mutual information and the 1000 
multi-resolution strategy of 4-levels of Gaussian smoothing were used. The resultant 1001 
transformation model, T , was applied to spatially-align a given m/z image to the 1002 
histological image, and then be aligned to immunofluorescence image using the 1003 
previously computed model T . 1004 
3) ROI and multi-modal correlation: We chose ROIs based on matching histology 1005 
between H&E and immunofluorescence slides because they are not the exactly same 1006 
slides and also excluded edge and folded areas due to strong auto-fluorescence 1007 
signals. In selected ROIs, signal intensities of MALDI-MSI images were quantified 1008 
based on the cellular markers defined by immunofluorescence images, using in-1009 
house Matlab codes. 1010 
Single cell RNA-sequencing of sorted TPCs Isolation of TPC cells for single cell RNA 1011 
sequencing was done on a BD Aria cell sorter, by sorting cells into 96 well plates 1012 
(Eppendorf) containing 10µl of lysis buffer (TCL buffer + 1% 2-mercaptoethanol). 1013 
Selection of cells was done using standard cell surface staining protocols with BV421-1014 
CD34 (BD sciences, 562608, 1:50), PE-CD49f (eBiosciences, 12-0495-81, 1:200), and by 1015 
gating on endogenous YFP expression in ROSA26-LSL-eYFP; Keratin14-Cre transgenic 1016 
mice. The viability dye propidium iodine (Sigma, P4864, 1:1000) was used to exclude 1017 
dead cell and was added after antibody labeling.  1018 
RNA isolation, and libraries generation was done by using a modified version of the 1019 
SmartSeq2 protocol as recently described48. Briefly, 22µl of Agencourt RNAClean XP 1020 
SPRI beads (Beckman Coulter, A63987) was added and mixed in the 96 well plates 1021 
containing sorted single cell lysates. After 10 minutes incubation, plates were placed 1022 
on a DynaMag-96 side skirted magnet (Invitrogen, 12027) for 5 minutes, followed by 1023 
supernatant removal and two washes with 75% ethanol. Next, dried beads were 1024 
mixed with 4µl of mix-1 containing 1µl (10µM) RT primer (IDT, DNA oligo) 5′–1025 
AAGCAGTGGTATCAACGCAGAGTACT30VN-3′ ; 1µl (10mM) dNTPs (Thermo-Fisher, 1026 
R0192); 1µl (4U/µl) Recombinant RNase Inhibitor (Clontech, 2313B); and 1µl nuclease 1027 
free water, and plates were placed in a thermocycler for 3 minutes at 72°C. After 1028 
RNA denaturation, reverse transcription (RT) step was done by adding, 7µl of mix-2 1029 
containing 0.75µl nuclease free water; 2µl 5X Maxima RT buffer (Thermo-Fisher, 1030 
EP0753); 2µl (5M) betaine (Sigma-Aldrich, B0300-1VL); 0.9µl (100mM) MgCl2 (Sigma-1031 
Aldrich, M1028); 1µl (10µM) TSO primer (Qiagen, RNA oligo) 5 ′ -1032 
AAGCAGTGGTATCAACGCAGAGTACATrGrG+G-3 ′ ; 0.25µl (40U/µl) Recombinant 1033 
RNase Inhibitor (Clontech, 2313B); and 0.1µl (200U/µl) of Maxima H Minus Reverse 1034 
Transcriptase (Thermo-Fisher, EP0753) was added and mixed followed by 90 minutes 1035 
incubation at 50°C and 5 minutes incubation at 85°C. For cDNA amplification, 14µl of 1036 
mix-3 containing 1µl nuclease free water; 0.5µl (10µM) ISPCR primer (IDT, DNA oligo) 1037 
5 ′ -AAGCAGTGGTATCAACGCAGAGT-3 ′ ; and 12.5µl 2X KAPA HiFi HotStart 1038 
ReadyMix (KAPA Biosystems, KK2602) was added and mixed, and plates were placed 1039 
for 3 minutes at 98°C, followed by 21 cycles at [98°C for 15 seconds, 67°C for 20 1040 
seconds and 72°C for 6 minutes] with final extension at 72°C for 5 minutes. Removal 1041 
of primer dimers after cDNA amplification was done by adding 20µl of Agencourt 1042 
AMPureXP SPRI beads (Beckman Coulter, A63881) to each well, incubation for 5 1043 
minutes, placement of plates on a DynaMag-96 side skirted magnet for 5 minutes, 1044 
followed by two 75% ethanol washes and resuspension of dried beads with 20µl TE 1045 
buffer (Tekanova, T0228). This step was repeated to ensure complete removal of 1046 
primer dimers. Quantification of the concentration of each cell was done on the 1047 
Cytation-5 plate reader (BioTek) by using the Qubit dsDNA high sensitivity assay 1048 
(Invitrogen, Q32854). For each plate, representative wells were also evaluated for 1049 
cDNA size distribution to ensure quality of sorted cells, using the High-sensitivity 1050 
DNA Bioanalyzer kit (Agilent 5067-4626). The Nextera XT library Prep kit (Illumina, 1051 
FC-131-1096) was used to generate libraries for next-generation sequencing. After 1052 
this step barcoded single cells were grouped into a single tube, followed by 1053 
sequencing on a NextSeq 500 sequencer (Illumina) using the 75 cycles kit, with 1054 
paired-end 38-base-reads and dual barcoding 8-base-reads.  1055 
Single cell RNA-seq data generation and processing FASTQ files were aligned to 1056 
the NCBI Genome Reference Consortium Mouse Build 38 (mm10) using STAR34. 1057 
Expression levels were computed using the RSEM tool and quantified as both raw 1058 
counts and Transcripts Per Million (TPM)49. For each cell, we used four quality control 1059 
(QC) metrics. We excluded: (1) cells expressing less than 2500 genes with three or 1060 
more counts, (2) cells with less than 500,000 RNA molecules detected, (3) cells with 1061 
mitochondrial gene counts exceeding 10% of total gene expression50, (4) cells with an 1062 
average expression of housekeeping genes48, log2(TPM+1) < 6.  1063 
Dimensionality reduction The t-Distributed Stochastic Neighbor Embedding (t-SNE) 1064 
and Uniform Manifold Approximation and Projection (UMAP) methods were used for 1065 
dimensionality reduction within the Seurat package51. The dimensionality of the 1066 
dataset was determined by Principal Component Analysis (PCA), and the first five 1067 
principal components (PCs) were used as inputs to the dimensionality reduction. 1068 
Unsupervised clustering of tumor cells TPCs were clustered using the R package 1069 
Seurat v. 3.1.151. The same PCs as in the dimensionality reduction were used as input 1070 
to the clustering analysis. The resolution parameter was set to 0.5 in order to identify 1071 
the greatest number of clusters with at least 20 significant marker genes. To be 1072 
considered a marker gene, the gene must be enriched in the given cluster with a 1073 
Wilcoxon Rank Sum test Bonferroni-adjusted p-value of less than 0.05 and a 1074 
minimum log-fold change of 0.25 when comparing the cells of the cluster to all 1075 
other cells. Statistical analysis was performed in R (version 3.6.1). 1076 
Pathway score analyses of TPCs from scRNA-seq For each single cell, we assigned 1077 
a score for each of several programs based on the average expression of a selected 1078 
gene set of interest minus the average of a control gene set, based on the work of 1079 
Puram, S.V. et al22. For glycolysis and glutathione metabolism, we began with a list of 1080 
relevant genes and calculated the Pearson correlation coefficient between all pairs of 1081 
genes in the list. We sequentially removed genes with the strongest negative 1082 
correlations to other genes until all genes were positively correlated in the list. Then, 1083 
we removed genes with the weakest positive correlations until all pairs of genes had 1084 
a Pearson correlation coefficient of at least 0.2. For the pentose phosphate pathway 1085 
and pro-differentiation, we followed a similar process of elimination, but stopped 1086 
eliminating genes once all correlations were positive, as the correlations were weaker. 1087 
For stemness, we used a list of genes associated with stemness but did not eliminate 1088 
any genes due to the genes on the list being largely uncorrelated. For antioxidant 1089 
response, we ranked the entire list of analyzed genes by their correlation with the 1090 
NRF2 transcription factor controlling the antioxidant response. We removed 1091 
unannotated genes to only include genes with known functions, and selected the top 1092 
30 positively correlated genes to make the gene list of interest. As described in 1093 
Puram, S.V. et al., the gene expression levels of a given program may be confounded 1094 
by the overall complexity of a given cell, since cells with high expression complexity 1095 
would be expected to score well for any given pathway. To control for this, the cell 1096 
score for a given pathway is defined as SCj(i) = average[Er(Gj,i)] – average[Er(Gjcont,i)], 1097 
where Gj is a given gene set, SCj(i) is the score of each cell i, and Er is average 1098 
relative expression. The cell score is then the score of the given pathway in that cell 1099 
minus the score of a control gene set. The control gene set is selected by dividing all 1100 
analyzed genes into 25 bins of equal size according to their overall expression, and 1101 
for each gene in Gj, selecting 100 genes from the same expression bin. 1102 
Trajectory analysis of TPCs To analyze the differentiation trajectory of the TPCs 1103 
based on the single-cell RNA-seq gene expression data, we used Monocle v. 2.13.052. 1104 
Monocle identified a set of 14,321 differentially expressed genes between the four 1105 
clusters established in Seurat. These genes were ordered by ascending q-value, and 1106 
the top 1000 genes were used as input to Monocle’s Reversed Graph Embedding 1107 
algorithm. Branched expression analysis modeling (BEAM) was used to identify genes 1108 
with branch-dependent expression, and a q-value cutoff of 1e-15 was applied. 1109 
Single cell transcriptomic analysis of human HNSCC patient samples We restricted 1110 
the analysis to malignant cells, as defined previously22 and scored each cell for each 1111 
program, based on the average expression of a set of pre-defined genes, minus the 1112 
average of a control gene-set (see Puram, S. V. et al. for further description of how 1113 
the control scores are selected). For glycolysis, we initially examined the gene 1114 
set PDK1, G6PD, PGD, PFKM, LDHB, LDHA. Since five of those genes were all 1115 
positively correlated with one another (across single cancer cells) while the sixth 1116 
(LDHA) was not correlated it was removed from the list, and the remaining five genes 1117 
were used to define final scores. For antioxidant gene score, we first calculated the 1118 
correlation of each gene with NRF2 across all cancer cells. We then selected the top 1119 
30 genes (including NRF2) to define antioxidant gene score (NRF2) scores. As 1120 
expected, this list includes many known downstream targets of NRF2 such as GPX2 1121 
and genes associated with detoxification/antioxidants etc.  1122 
 1123 
Statistics and Reproducibility  1124 
Figure 1, b, Statistical analysis was done by log-rank test (p= 0.0176). WT, n=9; cKO, 1125 
n=14. c, Student’s t-test was performed (two-sided). WT, n=34 biologically 1126 
independent tumors; cKO, n=36 biologically independent tumors. d, Fisher’s exact 1127 
test was performed for statistical analysis (p<0.0001, two-sided). WT, n=7; cKO, n=11. 1128 
e, (Upper panel) Student’s t-test was performed (p<0.0001, two-sided). At least 4 1129 
different measurements in 2 different microscopic images (40x) from 2 biologically 1130 
different samples were analyzed for normal skin samples. At least 4 different 1131 
measurements in 3 different microscopic images (40x) from 3 biologically different 1132 
samples were analyzed for tumor samples. The number of measurements as follows; 1133 
WT normal, n=16; cKO normal, n=16; WT tumor, n=34; cKO tumor, n=45. (Lower 1134 
panel) Immunostaining against PCNA was performed six times with similar results. g, 1135 
Student’s t-test was performed (two-sided). WT, n=34 biologically independent 1136 
tumors; cKO, n=36 biologically independent tumors; WT with DCA, n=28 biologically 1137 
independent tumors; cKO with DCA, n=43 biologically independent tumors. h, 1138 
Fisher’s exact test was performed for statistical analysis (p<0.0001, two-sided). WT, 1139 
n=7; cKO, n=11; WT with DCA, n=4; cKO with DCA, n=4. i, Immunostaining against 1140 
GLUT1 and p-PDH was performed ten and three times, respectively, with similar 1141 
results. 1142 
Figure 2, a, Immunofluorescent staining was performed five times with similar 1143 
results. e & f, Data is from at least two biological replicates (n=3 for WT and n=2 for 1144 
Sirt6 cKO), presented by mean. 1145 
Figure 3, a, Data is from three biological replicates. b, Data is from three biological 1146 
replicates. c, Student’s t-test was performed (two-sided). Data is from three biological 1147 
replicates. d, Student’s t-test was performed (two-sided). Data is from at least two 1148 
biological replicates (n=2 for shCtrl and n=3 for shSIRT6). e, Data is from two 1149 
biologically independent tumor samples, consisting of more than hundred thousands 1150 
of pixel datapoints per sample. f, Immunofluorescence staining was performed two 1151 
times with similar results. The nonparametric Wilcoxon rank sum test (two-sided and 1152 
95% significance level) was used after checking normality distribution using 1153 
Kolmogorov-Smirnov test. Details of the box plots are listed in the Source Data file 1. 1154 
g, Immunostaining was performed three times with similar results. 1155 
Figure 4, a, Data is always reproducible every time the code was run. The key point 1156 
for this stability is the random seed point in the t-SNE algorithm is set to zero and 1157 
that maintained reproducibility. The t-SNE analysis was done on MATLAB 2018a that 1158 
was installed on a workstation operating with Windows 10. d, right panel, ANOVA 1159 
test was performed. F values are as follows: Stemness, F=14.47; Pro-differentiation, 1160 
F=95.23. e, Pairwise comparisons using t-test were used to calculate p-value (p-value 1161 
adjustment was done by BH). g, Data is from three biological replicates. Paired 1162 
student t-test was performed (two-sided). 1163 
Extended Data Figure 1, a, Log-rank test was performed. b & c, left panels, Student 1164 
t-tests were performed. Details of the box plots are listed in the Source Data file 2. d, 1165 
Immunostaining was performed two times with similar results. 1166 
Extended Data Figure 2, b, Immunostaining was performed ten times for GLUT1 and 1167 
six times for PCNA with similar results. c, Each dot represents one biologically 1168 
independent tumor sample. (n=1, 2, 6, 5, respectively, from left to right in each 1169 
graph) Student’s t-tests were performed (two-sided). d, Immunostaining against 1170 
GLUT1, p-PDH, and MPC1 was performed ten, three, and two times, respectively, with 1171 
similar results. e, Definitions of each box plot are listed in Source Data file 3. f, 1172 
Immunostaining was performed two times with similar results. 1173 
Extended Data Figure 3, a & b, Immunostaining was performed three times with 1174 
similar results. Quantification is done by at least three independent 20x images with 1175 
hundreds of positive cells. c, Immunostaining was performed two times with similar 1176 
results. 1177 
Extended Data Figure 4, b, Each dot represents one biologically independent tumor 1178 
sample. (n= 2, 6, 3, 6, 5, 3 respectively, from left to right in each graph) Student’s t-1179 
tests were performed (two-sided). c, Each dot represents one biologically 1180 
independent tumor sample. (n= 6, 5, 3 respectively, from left to right in each graph) 1181 
Student’s t-tests were performed (two-sided). g & h, Data is from at least two 1182 
biological replicates (n=3 for WT and n=2 for Sirt6 cKO), presented by mean. 1183 
Extended Data Figure 5, b, Each dot represents one biologically independent 1184 
sample, presented by mean and S.D. (n=9 for S6HY and n=16 for S6WT). Student’s t-1185 
tests were performed (two-sided). c & e, Data is from three biological replicates. d, 1186 
Data is from three biological replicates. 1187 
Extended Data Figure 6, b, Data is from two independent experiments with two 1188 
experimental replicates. Student’s t-tests were performed (two-sided). c, 1189 
Immunostaining was performed three times with similar results. d, Immunostaining 1190 
was performed three times with similar results. e, Data is from three independent 1191 
experiments with two experimental replicates. Student’s t-tests were performed (two-1192 
sided). f-h, Data is from four biological replicates. Student’s t-tests were performed 1193 
(two-sided). i, Each dot represents one biologically independent sample, presented 1194 
by mean and S.D. (n=14 for shCtrl and n=14 for shSIRT6). Student’s t-tests were 1195 
performed (two-sided). j, Data is from three biological replicates. k, Data is from two 1196 
independent experiments with two experimental replicates. Student’s t-tests were 1197 
performed (two-sided). l & m, Data is from at least two biological replicates (n=2 for 1198 
shCtrl and n=3 for shSIRT6). 1199 
Extended Data Figure 7, a, Data is from three independent experiments (n=10 each 1200 
sample). Student’s t-tests were performed (two-sided). b, Data is from three 1201 
independent experiments. Two-way ANOVA test was performed. d, Two-way ANOVA 1202 
test was performed. e, Immunostaining was performed two times with similar results. 1203 
Extended Data Figure 8, a, Data is always reproducible every time the code was run. 1204 
The key point for this stability is the random seed point in the t-SNE algorithm is set 1205 
to zero and that maintained reproducibility. The t-SNE analysis was done on MATLAB 1206 
2018a that was installed on a workstation operating with Windows 10. c & e, Data is 1207 
from two biologically independent tumor samples, consisting of more than hundred 1208 
thousands of pixel datapoints per sample. d & f, The nonparametric Wilcoxon rank 1209 
sum test (two-sided and 95% significance level) was used after checking normality 1210 
distribution using Kolmogorov-Smirnov test. Details of the box plots are listed in the 1211 
Source Data file 4. g, Data is from two biologically independent tumor samples, 1212 
consisting of more than hundred thousands of pixel datapoints per sample. h, Data is 1213 
always reproducible every time the code was run. The key point for this stability is 1214 
the random seed point in the t-SNE algorithm is set to zero and that maintained 1215 
reproducibility. The t-SNE analysis was done on MATLAB 2018a that was installed on 1216 
a workstation operating with Windows 10. 1217 
Extended Data Figure 10, a, Each dot represents one biologically independent 1218 
tumor sample. (n= 5, 3, 10, 7, respectively, from left to right in each graph) Student’s 1219 
t-tests were performed (two-sided). b, Bright field imaging was performed two times 1220 
with similar results. 1221 
Supplementary Table 6, To be considered a marker gene, the gene must be 1222 
enriched in the given cluster with a Wilcoxon Rank Sum test Bonferroni-adjusted p-1223 
value of less than 0.05 and a minimum log-fold change of 0.25 when comparing the 1224 
cells of the cluster to all other cells. Statistical analysis was performed in R (version 1225 
3.6.1). 1226 
 1227 
Reporting Summary 1228 
Further information on research design is available in the Nature Research Reporting 1229 
Summary linked to this article. 1230 
 1231 
Data availability 1232 
The RNA-seq data of the tumor subpopulations from mouse cutaneous tumors of 1233 
Sirt6 WT or cKO animals have been submitted to the Gene Expression Omnibus 1234 
(GEO) database under accession number GSE115953 (Related to Fig. 2d-f and 1235 
Extended Data Fig. 4e-h). The scRNA-seq data of tumor-propagating cells from 1236 
mouse cutaneous tumors of Sirt6 WT or cKO animals have been submitted to the 1237 
Gene Expression Omnibus (GEO) database under accession number GSE147031 1238 
(Related to Fig. 4b-e and Extended Data Fig. 9a-j). There is no restriction on data 1239 
availability. Human HNSCC scRNA-seq data from Puram S.V. et al. is available in 1240 
GSE103322 (Related to Fig. 4h and Extended Data Fig. 10c-d). Oncomine and TCGA 1241 
dataset (Related to Extended Data Fig.1a-c & 2e) is available in cBioportal 1242 
(cbioportal.org). Cancer Cell Line Encyclopedia data (Related to Extended Data Fig.1e) 1243 
is available in portals.broadinstitute.org/ccle. Source Data are provided with this 1244 
article. 1245 
 1246 
Code availability 1247 
All the in-house codes were previously used in the published works. Appropriate 1248 
references to the original works have been included. 1249 
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Correspondence and request of materials should be addressed to Raul Mostoslavsky. 1251 
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